[ad_1]
Shares of DexCom Inc. tumbled more than 40% on Friday and were headed for their worst percentage drop on record, a day after the maker of diabetes-management equipment shocked investors with a cut to its sales forecast that heightened concerns about growing global competition and the company’s prospects overall.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...